Literature DB >> 3596167

Effects of cisapride on gastric and esophageal emptying in progressive systemic sclerosis.

M Horowitz, G J Maddern, A Maddox, J Wishart, B E Chatterton, D J Shearman.   

Abstract

The effects of cisapride on gastric emptying, esophageal emptying, and gastrointestinal symptoms were evaluated in 8 patients with progressive systemic sclerosis who had delayed gastric emptying of the solid or liquid component of a meal, or both. A double-isotope technique was used to measure gastric emptying, and esophageal emptying was measured as the time for a bolus of the solid meal to enter the stomach. Gastrointestinal symptoms were assessed by a questionnaire. On 2 days each patient received cisapride (10 mg) or placebo intravenously, 5 min before an esophageal and gastric emptying test. After these 2 days each subject took cisapride (10 mg q.i.d., p.o.) for 1 mo. Cisapride improved solid and liquid gastric emptying (p less than 0.001), but had no significant effect on esophageal emptying (p less than 0.1). Upper gastrointestinal symptoms were reduced after cisapride (p less than 0.001), and no side effects were reported. These results indicate that gastroparesis is a treatable cause of morbidity in progressive systemic sclerosis.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3596167     DOI: 10.1016/0016-5085(87)91020-1

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  26 in total

Review 1.  The current treatment of scleroderma.

Authors:  G F Oliver; R K Winkelmann
Journal:  Drugs       Date:  1989-01       Impact factor: 9.546

2.  Cisapride in intensive care.

Authors:  L F Lauwers
Journal:  Intensive Care Med       Date:  1991       Impact factor: 17.440

3.  Slow gastric emptying induced by high fat content of meal accelerated by cisapride administered rectally.

Authors:  G Stacher; G V Granser; H Bergmann; A Kugi; G Stacher-Janotta; J Höbart
Journal:  Dig Dis Sci       Date:  1991-09       Impact factor: 3.199

4.  [Effect of cisapride on esophageal motility in healthy probands and patients with progressive systemic scleroderma].

Authors:  T Wehrmann; W F Caspary
Journal:  Klin Wochenschr       Date:  1990-06-19

Review 5.  What are the important subsets of gastroparesis?

Authors:  M Camilleri; M Grover; G Farrugia
Journal:  Neurogastroenterol Motil       Date:  2012-05-24       Impact factor: 3.598

6.  [Chronic motility disorders of the upper gastrointestinal tract in the elderly. Pharmaceutical, endoscopic and operative therapy].

Authors:  J-U Sonne; J F Erckenbrecht
Journal:  Internist (Berl)       Date:  2014-07       Impact factor: 0.743

Review 7.  Rational pharmacotherapy of gastrointestinal motility disorders.

Authors:  P Demol; H J Ruoff; T R Weihrauch
Journal:  Eur J Pediatr       Date:  1989-04       Impact factor: 3.183

8.  Postprandial antropyloroduodenal motility and gastric emptying in gastroparesis--effects of cisapride.

Authors:  R J Fraser; M Horowitz; A F Maddox; J Dent
Journal:  Gut       Date:  1994-02       Impact factor: 23.059

Review 9.  Diabetic gastroparesis: diagnosis and management.

Authors:  Jing Ma; Christopher K Rayner; Karen L Jones; Michael Horowitz
Journal:  Drugs       Date:  2009-05-29       Impact factor: 9.546

Review 10.  Medical treatment of esophageal motility disorders.

Authors:  H D Allescher; W J Ravich
Journal:  Dysphagia       Date:  1993       Impact factor: 3.438

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.